High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity

Journal of Alzheimer's Disease

Volumn 53, Issue 4, 2016, Pages 1499-1516

  Qosa, Hisham ^a   Mohamed, Loqman A ^a   Al Rihani, Sweilem B ^a   Batarseh, Yazan S ^a   Duong, Quoc Viet ^a   Keller, Jeffrey N ^b   Kaddoumi, Amal ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Amyloid ; Blood brain barrier; High throughput screening; Permeability; Repurposing

Indexed keywords

AMYLOID BETA PROTEIN; ATOMOXETINE; BECLOMETASONE; BEXAROTENE; CANDESARTAN; CLAUDIN 5; COLCHICINE; DEMECLOCYCLINE; ETODOLAC; FELODIPINE; GRANISETRON; IDARUBICIN; LUCIFER YELLOW; NEUROPROTECTIVE AGENT; OXAPROZIN; OXYBUTYNIN; PANCURONIUM; RESERPINE; TOPOTECAN; VINBLASTINE; VINCRISTINE; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL CULTURE; COMPUTER MODEL; CONTROLLED STUDY; DRUG PENETRATION; DRUG REPOSITIONING; EC50; ENDOTHELIUM CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE PERMEABILITY; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR AMYLOIDOSIS; ANIMAL; BIOLOGICAL MODEL; BRAIN; CHEMISTRY; COCULTURE; CYTOLOGY; DRUG EFFECTS; LIBRARY; METABOLISM; PERMEABILITY; PROCEDURES; TRANSFORMED CELL LINE; TRANSPORT AT THE CELLULAR LEVEL;

AMYLOID BETA-PEPTIDES; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE, TRANSFORMED; CLAUDIN-5; COCULTURE TECHNIQUES; DRUG REPOSITIONING; ENDOTHELIAL CELLS; IN VITRO TECHNIQUES; LIBRARIES, SPECIAL; MICE; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; PERMEABILITY;

EID: 84981709139     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-151179     Document Type: Article

References (84)

1. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201.
2. Banks WA (2009) Characteristics of compounds that cross the blood-brain barrier. BMC Neurol 9(Suppl 1), S3.
3. Hawkins BT, Davis TP (2005) The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57, 173-185.
4. Abbott NJ, Ronnback L, Hansson E (2006) Astrocyteendothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7, 41-53.
5. Rosenberg GA (2012) Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab 32, 1139-1151.
6. Zhong Z, Deane R, Ali Z, Parisi M, ShapovalovY, O'Banion MK, Stojanovic K, Sagare A, Boillee S, Cleveland DW, Zlokovic BV (2008) ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci 11, 420-422.
7. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118, 103-113.
8. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA (2007) Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 27, 697-709.
9. Leppert D, Lindberg RL, Kappos L, Leib SL (2001) Matrix metalloproteinases: Multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev 36, 249-257.
10. Henderson AP, Barnett MH, Parratt JD, Prineas JW (2009) Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions. Ann Neurol 66, 739-753.
11. Gonzalez-Velasquez FJ, Kotarek JA, Moss MA (2008) Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers. J Neurochem 107, 466-477.
12. Qosa H, Abuznait AH, Hill RA, Kaddoumi A (2012) Enhanced brain amyloid-beta clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J Alzheimers Dis 31, 151-165.
13. Brenn A, Grube M, Peters M, Fischer A, Jedlitschky G, Kroemer HK, Warzok RW, Vogelgesang S (2011) Betaamyloid downregulates MDR1-P-Glycoprotein (Abcb1) expression at the blood-brain barrier in mice. Int J Alzheimers Dis 2011, 690121.
14. Abbott NJ, Dolman DE, Patabendige AK (2008) Assays to predict drug permeation across the blood-brain barrier, and distribution to brain. Curr Drug Metab 9, 901-910.
15. Wong AD, Ye M, Levy AF, Rothstein JD, Bergles DE, Searson PC (2013) The blood-brain barrier: An engineering perspective. Front Neuroeng 6, 7.
16. Geldenhuys WJ, Allen DD, Bloomquist JR (2012) Novel models for assessing blood-brain barrier drug permeation. Expert Opin Drug Metab Toxicol 8, 647-653.
17. Deguchi Y, Morimoto K (2001) Application of an in vivo brain microdialysis technique to studies of drug transport across the blood-brain barrier. Curr Drug Metab 2, 411-423.
18. Wilhelm I, Fazakas C, Krizbai IA (2011) In vitro models of the blood-brain barrier. Acta Neurobiol Exp (Wars) 71, 113-128.
19. Steiner O, Coisne C, Engelhardt B, Lyck R (2011) Comparison of immortalized bEnd5 and primary mouse brain microvascular endothelial cells as in vitro blood-brain barrier models for the study of T cell extravasation. J Cereb Blood Flow Metab 31, 315-327.
20. Brown RC, Morris AP, O'Neil RG (2007) Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 1130, 17-30.
21. Hellinger E, Veszelka S, Toth AE, Walter F, Kittel A, Bakk ML, Tihanyi K, Hada V, Nakagawa S, Duy TD, Niwa M, Deli MA, Vastag M (2012) Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur J Pharm Biopharm 82, 340-351.
22. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO (2005) Blood-brain barrierspecific properties of a human adult brain endothelial cell line. FASEB J 19, 1872-1874.
23. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck MP, Fenart L (2007) Modelling of the bloodbrain barrier in drug discovery and development. Nat Rev Drug Discov 6, 650-661.
24. Zehendner CM, Librizzi L, de Curtis M, Kuhlmann CR, Luhmann HJ (2011) Caspase-3 contributes to ZO-1 and Cl-5 tight-junction disruption in rapid anoxic neurovascular unit damage. PLoS One 6, e16760.
25. Omidi Y, Campbell L, Barar J, Connell D, Akhtar S, GumbletonM( 2003) Evaluation of the immortalised mouse brain capillary endothelial cell line, b. End3, as an in vitro bloodbrain barrier model for drug uptake and transport studies. Brain Res 990, 95-112.
26. Eigenmann DE, Xue G, Kim KS, Moses AV, Hamburger M, OufirM(2013) Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies. Fluids Barriers CNS 10, 33.
27. Cooray HC, Shahi S, Cahn AP, van Veen HW, Hladky SB, Barrand MA (2006) Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids. Eur J Pharmacol 531, 25-33.
28. Stamatovic SM, Dimitrijevic OB, Keep RF, AndjelkovicAV (2006) Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. J Biol Chem 281, 8379-8388.
29. Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4, 67-73.
30. Wu G (2010) Assay development: Fundamentals and practices, Wiley, Hoboken, N.J.
31. Varma H, Lo DC, Stockwell BR (2011) High-throughput and high-content screening for Huntington's disease therapeutics. In Neurobiology of Huntington's disease: Applications to drug discovery, Lo DC, Hughes RE, eds., CRC Press, Boca Raton.
32. Chung N, Zhang XD, Kreamer A, Locco L, Kuan PF, Bartz S, Linsley PS, Ferrer M, Strulovici B (2008) Median absolute deviation to improve hit selection for genome-scale RNAi screens. J Biomol Screen 13, 149-158.
33. Qosa H, LeVine H, 3rd, Keller JN, Kaddoumi A (2014) Mixed oligomers and monomeric amyloid-beta disrupts endothelial cells integrity and reduces monomeric amyloidbeta transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model. Biochim Biophys Acta 1842, 1806-1815.
34. Qosa H, Batarseh YS, Mohyeldin MM, El Sayed KA, Keller JN, Kaddoumi A (2015) Oleocanthal enhances amyloidbeta clearance from the brains of TgSwDi mice and in vitro across a human blood-brain barrier model. ACS Chem Neurosci 6, 1849-1859.
35. Qosa H, Abuasal BS, Romero IA, Weksler B, Couraud PO, Keller JN, Kaddoumi A (2014) Differences in amyloidbeta clearance across mouse and human blood-brain barrier models: Kinetic analysis and mechanistic modeling. Neuropharmacology 79, 668-678.
36. Hartmann C, Zozulya A, Wegener J, Galla HJ (2007) The impact of glia-derived extracellular matrices on the barrier function of cerebral endothelial cells: An in vitro study. Exp Cell Res 313, 1318-1325.
37. Tilling T, Engelbertz C, Decker S, Korte D, Huwel S, Galla HJ (2002) Expression and adhesive properties of basement membrane proteins in cerebral capillary endothelial cell cultures. Cell Tissue Res 310, 19-29.
38. Wuest DM, Wing AM, Lee KH (2013) Membrane configuration optimization for a murine in vitro blood-brain barrier model. J Neurosci Methods 212, 211-221.
39. Hulper P, Veszelka S, Walter FR, WolburgH, Fallier-Becker P, Piontek J, Blasig IE, Lakomek M, Kugler W, Deli MA (2013) Acute effects of short-chain alkylglycerols on bloodbrain barrier properties of cultured brain endothelial cells. Br J Pharmacol 169, 1561-1573.
40. Kashiwamura Y, Sano Y, Abe M, Shimizu F, Haruki H, Maeda T, Kawai M, Kanda T (2011) Hydrocortisone enhances the function of the blood-nerve barrier through the up-regulation of claudin-5. Neurochem Res 36, 849-855.
41. Forster C, Burek M, Romero IA, Weksler B, Couraud PO, Drenckhahn D (2008) Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol 586, 1937-1949.
42. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37, 13-25.
43. Winkler EA, Bell RD, Zlokovic BV (2011) Central nervous system pericytes in health and disease. Nat Neurosci 14, 1398-1405.
44. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV (2010) Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68, 409-427.
45. SofroniewMV, Vinters HV (2010) Astrocytes: Biology and pathology. Acta Neuropathol 119, 7-35.
46. Fernández-Klett F, Potas JR, Hilpert D, Blazej K, Radke J, Huck J, Engel O, Stenzel W, Genové G, Priller J (2013) Early loss of pericytes and perivascular stromal cell-induced scar formation after stroke. J Cereb Blood Flow Metab 33, 428-439.
47. Price TO, Eranki V, Banks WA, Ercal N, Shah GN (2012) Topiramate treatment protects blood-brain barrier pericytes from hyperglycemia-induced oxidative damage in diabetic mice. Endocrinology 153, 362-372.
48. Dore-Duffy P, Owen C, Balabanov R, Murphy S, Beaumont T, Rafols JA (2000) Pericyte migration from the vascular wall in response to traumatic brain injury. Microvasc Res 60, 55-69.
49. Wilhelmus MM, Otte-Holler I, van Triel JJ, Veerhuis R, Maat-Schieman ML, Bu G, de Waal RM, Verbeek MM (2007) Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. Am J Pathol 171, 1989-1999.
50. Sagare AP, Bell RD, Zhao Z, Ma Q, Winkler EA, Ramanathan A, Zlokovic BV (2013) Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun 4, 2932.
51. Watanabe T, Dohgu S, Takata F, Nishioku T, Nakashima A, Futagami K, Yamauchi A, Kataoka Y (2013) Paracellular barrier and tight junction protein expression in the immortalized brain endothelial cell lines bEND. 3, bEND. 5 and mouse brain endothelial cell 4. Biol Pharm Bull 36, 492-495.
52. Yuan W, Li G, Gil ES, Lowe TL, Fu BM (2010) Effect of surface charge of immortalized mouse cerebral endothelial cell monolayer on transport of charged solutes. Ann Biomed Eng 38, 1463-1472.
53. Jo DG, Arumugam TV, Woo HN, Park JS, Tang SC, Mughal M, Hyun DH, Park JH, Choi YH, Gwon AR, Camandola S, Cheng A, Cai H, Song W, Markesbery WR, Mattson MP (2010) Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer's disease. Neurobiol Aging 31, 917-925.
54. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R (2006) Statistical practice in high-throughput screening data analysis. Nat Biotechnol 24, 167-175.
55. McClung HJ, Sloan HR, Powers P, Merola AJ, Murray R, Kerzner B, Pollack JD (1990) Early changes in the permeability of the blood-brain barrier produced by toxins associated with liver failure. Pediatr Res 28, 227-231.
56. Appleby BS, Cummings JL (2013) Discovering new treatments for Alzheimer's disease by repurposing approved medications. Curr Top Med Chem 13, 2306-2327.
57. Corbett A, Ballard C (2013) Is a potential Alzheimer's therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms? Expert Opin Investig Drugs 22, 941-943.
58. Shehata IA, Ballard JR, Casper AJ, Hennings LJ, Cressman E, Ebbini ES (2014) High-intensity focused ultrasound for potential treatment of polycystic ovary syndrome: Toward a noninvasive surgery. Fertil Steril 101, 545-551.
59. Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. J Neurochem 110, 1129-1134.
60. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat Med 6, 143-150.
61. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D (2003) Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: A hypothesis. Lancet Neurol 2, 506-511.
62. Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B (2000) Clearance of amyloid beta-peptide from brain: Transport or metabolism? Nat Med 6, 718-719.
63. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115, 3285-3290.
64. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptorrelated protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499.
65. Giannoni P, Arango-Lievano M, Neves ID, Rousset MC, Baranger K, Rivera S, Jeanneteau F, Claeysen S, Marchi N (2016) Cerebrovascular pathology during the progression of experimental Alzheimer's disease. Neurobiol Dis 88, 107-117.
66. Park L, Zhou J, Zhou P, Pistick R, El Jamal S, Younkin L, Pierce J, Arreguin A, Anrather J, Younkin SG, Carlson GA, McEwen BS, Iadecola C (2013) Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. Proc Natl Acad Sci U S A 110, 3089-3094.
67. Paul J, Strickland S, Melchor JP (2007) Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 204, 1999-2008.
68. Carrano A, Hoozemans JJ, van derVies SM, Rozemuller AJ, van Horssen J, de Vries HE (2011) Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 15, 1167-1178.
69. Hartz AM, Bauer B, Soldner EL, Wolf A, Boy S, Backhaus R, Mihaljevic I, Bogdahn U, Klunemann HH, Schuierer G, Schlachetzki F (2012) Amyloid-beta contributes to bloodbrain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke 43, 514-523.
70. Tai LM, Holloway KA, Male DK, Loughlin AJ, Romero IA (2010) Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med 14, 1101-1112.
71. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12, 723-738.
72. Dorr A, Sahota B, Chinta LV, Brown ME, Lai AY, Ma K, Hawkes CA, McLaurin J, Stefanovic B (2012) Amyloidbeta-dependent compromise of microvascular structure and function in a model of Alzheimer's disease. Brain 135, 3039-3050.
73. Mawuenyega KG, SigurdsonW, OvodV, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Scienc 330, 1774.
74. Chugh Y, Saha N, Sankaranarayanan A, Sharma PL (1991) Memory enhancing effects of granisetron (BRL 43694) in a passive avoidance task. Eur J Pharmacol 203, 121-123.
75. Ju Yeon Ban, Yeon Hee, Seong (2005) Blockade of 5-HT(3) receptor with MDL 72222 and Y 25130 reduces beta-amyloid protein (25-35)-induced neurotoxicity in cultured rat cortical neurons. Eur J Pharmacol 520, 12-21.
76. Javadi-Paydar M, Zakeri M, Norouzi A, Rastegar H, Mirazi N, Dehpour AR (2012) Involvement of nitric oxide in granisetron improving effect on scopolamine-inducedmemory impairment in mice. Brain Res 1429, 61-71.
77. in t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van DuijnCM, StijnenT, BretelerMM, Stricker BH (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345, 1515-1521.
78. Yip AG, Green RC, Huyck M, Cupples LA, Farrer LA, Mirage Study Group (2005) Nonsteroidal antiinflammatory drug use and Alzheimer's disease risk: The MIRAGE study. BMC Geriatr 5, 2.
79. Wang J, Tan L, Wang HF, Tan CC, Meng XF, Wang C, Tang SW, Yu JT (2015) Anti-inflammatory drugs and risk of Alzheimer's disease: An updated systematic review and meta-analysis. J Alzheimers Dis 44, 385-396.
80. Choi JK, Carreras I, Aytan N, Jenkins-Sahlin E, Dedeoglu A, Jenkins BG (2014) The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer's disease mouse model using magnetic resonance spectroscopy and imaging. Brain Res 1590, 85-96.
81. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23, 7504-7509.
82. Pasinetti GM (2002) From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: The role of NSAIDs and cyclooxygenase in betaamyloidosis and clinical dementia. J Alzheimers Dis 4, 435-445.
83. Szekely CA, Zandi PP (2010) Non-steroidal antiinflammatory drugs and Alzheimer's disease: The epidemiological evidence. CNS Neurol Disord Drug Targets 9, 132-139.
84. ADAPT-FS Research Group (2015) Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study. Alzheimers Dement 11, 216-225.